Clinical trial
Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque…
NCT00192517 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00192517 |
|---|---|
| Title | Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis |
| Official title | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of MEDI-522, a Humanized Monoclonal Antibody to Integrin Alpha V Beta 3, Administered by Subcutaneous Injection to Adults With Plaque Psoriasis |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug, Other |
| Interventions | MEDI-522, Placebo |
| Enrollment | 44 |
| Start date | Dec 1, 2003 |
| Primary completion | Aug 1, 2004 |
| Completion | Sep 1, 2004 |
| First posted | Sep 19, 2005 |
| Last update posted | Apr 3, 2009 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: